What is Dihexa?
Dihexa is a small angiotensin IV-derived molecule discussed in peptide markets because of nootropic and neurotrophic claims. It is not a conventional short peptide protocol with a clinical-use pathway. [1][2][4]
The key evidence issue is credibility. A prominent HGF/c-Met mechanism paper tied to Dihexa was retracted, and the related prodrug fosgonimeton has not produced a clean disease-modifying win in Alzheimer disease development. [1][2][4]
Those facts do not prove Dihexa has no biology, but they sharply lower confidence in broad cognitive-enhancement claims. [1][2][4]
What Dihexa is investigated for
Dihexa evidence is grouped by practical use case and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Cognitive enhancement
Oral
Cognitive enhancement
Oral
Memory improvement
Oral
Memory improvement
Oral
Evidence snapshot
Overall confidence
Dihexa has no direct human outcome base, and part of the proposed mechanism has retraction history. Alzheimer and nootropic uses remain unproven signals. [1][2][4][5]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Related fosgonimeton development provides background for the pathway, but it is not direct Dihexa efficacy evidence. No controlled human Dihexa cognition trial establishes benefit. [1][2][4][5]
Animal / preclinical
The proposed neurotrophic pathway remains scientifically interesting but unsettled. Retraction history lowers confidence in the preclinical base. [1][2][4][5]
Mechanism support
Dihexa has been described as an angiotensin IV analog with proposed HGF/c-Met pathway effects. The proposed benefit is synapse-support biology, but translation has not been shown in humans. [1][2][4][5]
Forms & administration
Dihexa is tracked as an oral research-market compound. Dihexa capsule-style use is separate from fosgonimeton and other hepatocyte-growth-factor-pathway clinical-development drugs. [11][1][2]
Dosing & protocols
The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.
Typical Range
Common oral protocols usually use 10-20 mg per day. [11][1][2]
Frequency
Timing Considerations
Morning timing is the common anchor so attention, sleep, and stimulant overlap are easier to separate. [11][1][2]
Cycle Length
Common oral blocks run 4-8 weeks before comparing focus, sleep, mood, and adverse-effect notes with baseline. [11][1][2]
What to expect
First 1-2 weeks
Oral Dihexa use may feel like changes in focus, mental stamina, task initiation, or motivation during ordinary work and study routines. [1][2][4][5][11]
Weeks 4-8
Oral cognition-oriented effects may appear as steadier task consistency, memory routines, mood, or sleep patterns. [1][2][4][5][11]
After stopping
Perceived focus, motivation, or cognitive stamina may drift back toward baseline after oral Dihexa exposure ends. [1][2][4][5][11]
Safety profile
Dihexa safety centers on neuroactive effects, product identity, and sparse direct human safety data. [1][2][4][5]
Who Dihexa is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Stimulants / wakefulness drugs
Amphetamines, methylphenidate, modafinil, or high-caffeine nootropics can compound insomnia, anxiety, or overstimulation; this is a theoretical neuroactive caution. [1][2][4][5]
- Sedatives / alcohol
Alcohol, benzodiazepines, sleep drugs, or sedating supplements can obscure cognition, coordination, and next-day effects; this is a theoretical neuroactive caution. [1][2][4][5]
- Psychiatric / seizure-threshold drugs
Antidepressants, antipsychotics, or seizure-threshold-active drugs can make mood or neurologic changes harder to attribute; this is a theoretical neuroactive caution. [1][2][4][5]
Regulatory status
United States
In the U.S. as of 2026-06-21, Dihexa is not FDA-approved for the reviewed oral route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval. [17][11][12][15][16]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved Dihexa is not FDA-approved as an oral drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [11][12][15][16] | Flagged FDA safety-risk materials flag dihexa acetate because human exposure data and core human safety information are missing. This is a 503A compounding safety-risk bucket, not FDA drug approval. [17][11][12][15][16] |
Oral
International
EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [18][19][20][21]
Sports & competition
WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Dihexa oral route as athlete-cleared without sport-specific review. [13][11][12][15][16]
How it works
Dihexa has been described as an angiotensin IV analog with proposed HGF/c-Met effects, meaning a pathway once framed around synapse formation and neuronal support. That biology is attractive for cognition claims, but it is no longer a clean foundation. [1][2][4][5]
The central mechanism paper was retracted, and the related fosgonimeton development story has not produced a settled disease-modifying Alzheimer outcome. Oral research-market exposure also leaves blood-brain delivery, dose, and safety questions separate from the original pathway hypothesis. Independent replication would be needed before the mechanism can anchor user-facing benefit claims. [1][2][4][5]
Research gaps & open questions
What the current literature has not yet settled about Dihexa:
Common questions
Is Dihexa a peptide?
Was a key Dihexa paper retracted?
Myths & misconceptions
History & discovery
Dihexa became visible through angiotensin IV analog research that proposed HGF/c-Met synaptogenic signaling as a cognition route. Its history later changed because evidence-quality and translation questions became central. [1][2][4][5]
Early papers framed Dihexa and related analogs as small molecules for Alzheimer and Parkinson disease concepts. That positioned Dihexa around synapse-support biology before any practical human protocol existed. [1][2][4][5]
A retraction tied to the HGF/Met analog program and mixed fosgonimeton development results weakened the original mechanism story. The history now argues for caution, replication, and human outcome evidence. [1][2][4][5]
13 studies
The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system.
J Pharmacol Exp Ther, 2014 Nov. review.
Retraction notice to "Development of Angiotensin IV Analogs as Hepatocyte Growth Factor/Met Modifiers" [J Pharmacol Exp Ther 340 (2012) 539-548].
J Pharmacol Exp Ther, 2025 Apr. review.
Retraction notice to "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System" [J Pharmacol Exp Ther 351 (2014) 390-402].
J Pharmacol Exp Ther, 2025 Apr. review.
Fosgonimeton in mild-to-moderate Alzheimer's disease.
J Alzheimers Dis Rep, 2025 Jan-Dec. human clinical.
The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.
Prog Neurobiol, 2015 Feb. review.
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.
Brain Sci, 2021 Nov 11. animal.
Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.
J Pharmacol Exp Ther, 2013 Jan. animal.
Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches.
Medicina (Kaunas), 2023 Oct 1. review.
Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics.
PCN Rep, 2024 Mar. review.
Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies.
Ann Med Surg (Lond), 2021 Nov. animal.
Drugs@FDA/openFDA query for Dihexa
U.S. Food and Drug Administration. database query.
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration. official guidance.
The 2026 List of Prohibited Substances and Methods
World Anti-Doping Agency. regulatory.